Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to ...

Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

The AAN updates guidance on driving with seizures, reporting, and licensure based on the latest evidence to promote fair, individualized assessments.

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

为评估 Cenobamate（CNB）作为超难治性局灶性癫痫附加治疗的长期疗效、耐受性及对联合抗癫痫药物（ASM）的影响，丹麦癫痫中心研究人员开展相关研究。结果显示部分患者有效，且不良反应可调整处理。该研究为 CNB 临床应用提供依据。

Argent BioPharma and AusCann Group join forces through a new strategic agreement to advance cannabinoid-based pharmaceutical development. ... Read More The post Argent and AusCann partner to ...

4月11日，国家自然科学基金委员会网站通报了2025年第一批科研不端案件处理结果，共涉及15起案件。其中，内蒙古民族大学魏成喜、宫国华、安凤毛、张彬、付丹妮等分别为相关责任作者发表的10篇论文涉嫌学术不端。

为探究 LMAN2L 基因突变与癫痫的关系，山东大学齐鲁医院研究人员开展对携带 LMAN2L 基因突变家庭的研究。结果发现 2 个新的 LMAN2L 复合杂合变异，导致难治性癫痫。该研究首次将 LMAN2L 与癫痫性脑病及难治性癫痫表型关联，丰富了 LMAN2L 基因致病变异谱。

Epilepsy, a seizure disorder that affects about 50 million people worldwide, often disrupts memory, emotions and sleep. Many cases are drug-resistant, leaving people with limited treatment options.

For many people, epilepsy is a condition which can be well-managed and has little or no impact on their life. For others, ongoing seizures mean that epilepsy has a long-term impact on them. Like some ...

He had progressive fatigue and shortness of breath, which had prompted laboratory investigations by his family physician. His medical history included 18 years of warts on his extremities, which were ...